Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates

Pharmacogenetics and Genomics

Volumn 17, Issue 12, 2007, Pages 1017-1029

  Udomuksorn, Wandee ^a,b   Elliot, David J ^a   Lewis, Benjamin C ^a   Mackenzie, Peter I ^a   Yoovathaworn, Krongtong ^b   Miners, John O ^a,c  

^a FLINDERS UNIVERSITY   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Bilirubin; Crigler Najjar syndrome type II; Gilbert syndrome; Glucuronidation; UDP glucuronosyltransferase; UGT1A1 genetic polymorphism

Indexed keywords

1 NAPHTHOL; BILIRUBIN; COMPLEMENTARY DNA; ESTRADIOL; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; HYMECROMONE; NAPROXEN; 1-NAPHTHOL; 4-METHYLUMBELLIFERONE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; DRUG DERIVATIVE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; NAPHTHOL DERIVATIVE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MUTANT; CELL STRAIN HEK293; CRIGLER NAJJAR SYNDROME; CRIGLER NAJJAR TYPE II SYNDROME; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE MUTATION; GILBERT DISEASE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; WILD TYPE; AMINO ACID SUBSTITUTION; CELL LINE; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; KINETICS; METABOLISM; PHARMACOGENETICS; POINT MUTATION;

AMINO ACID SUBSTITUTION; BILIRUBIN; CELL LINE; CRIGLER-NAJJAR SYNDROME; ESTRADIOL; GILBERT DISEASE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; KINETICS; MUTAGENESIS, SITE-DIRECTED; NAPHTHOLS; PHARMACOGENETICS; POINT MUTATION; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 34748822655     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328256b1b6     Document Type: Article

References (44)

1. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51:347-369.
2. Radominska-Pandaya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31:817-899.
3. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferase: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616.
4. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S-I, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 2005; 15:677-685.
5. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: application of in-vitro and in-silico modeling approaches. Annu Rev Pharmacol Toxicol 2004; 44:1-25.
6. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002; 181-182:453-456.
7. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdury NR. Genetic lesions of bilirubin uridine-diphospho-glucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16:297-306.
8. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003; 38:107-117.
9. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoforms 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
10. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303:233-240.
11. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP- glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002; 12:635-645.
12. Koiwai O, Nishizawa M, Hasada K, Aono S, Adachi Y, Mamiya N, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995; 4:1183-1186.
13. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene of phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1998; 1406:267-273.
14. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46:21-26.
15. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphosphate- glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19:1023-1028.
16. Sutomo R, Laosombat V, Sadewa AH, Yokoyama N, Nakamura H, Matsuo M, et al. Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome. Pediatr Int 2002; 44:427-432.
17. Kamisako T. What is Gilbert's syndrome? Lesson from genetic polymorphisms of UGT1A1 in Gilbert's syndrome from Asia. J Gastroenterol Hepatol 2004; 19:955-957.
18. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170-8174.
19. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of in-vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65:576-582.
20. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.
21. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31:108-113.
22. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African American. Drug Metab Dispos 2005; 33:468-465.
23. Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenetics of human UDP-glucuronosyltranferases and irinotecan toxicity. Mol Pharmacol 2002; 62:446-450.
24. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
25. Ito M, Yamamoto K, Maruo Y, Sato H, Fujiyama Y, Bamba T. Effect of a conserved mutation in uridine diphosphate glucuronosyltransferase 1A1 and 1A6 on glucuronidation of a metabolite of flutamide. Eur J Clin Pharmacol 2002; 58:11-14.
26. Kurkela M, Hirvonen J, Kostiainen R, Finel M. The interactions between the N-terminal and C-terminal domains of the human UDPglucuronosyltransferases are partly isoform-specific, and may involve both monomers. Biochem Pharmacol 2004; 68:2443-2450.
27. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, et al. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004; 32:413-423.
28. Lepine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, et al. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 2004; 89:5222-5232.
29. Miners JO, Knights KM, Houston JB, Mackenzie PI. In-vitro - in-vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 2006; 71:1531-1539.
30. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, Miners JO. S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 2005; 60:423-433.
31. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 2003; 31:1086-1089.
32. Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson LH. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000; 206:17-26.
33. McDonagh AF, Assisi F. Commercial bilirubin: a trinity of isomers. FEBS Lett 1971; 18:315-317.
34. Odell GB, Mogilevsky WS, Gourley GR. High-performance liquid chromatographic analysis of bile pigment as their native tetrapyrroles and as their dipyrrolic azosulfanilate derivatives. J Chromatogr 1990; 529:287-298.
35. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In-vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in-vivo bilirubin glucuronidation. Drug Metab Disp 2005; 33:1729-1739.
36. Houston JB, Kenworthy KE. In-vitro - in-vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 2000; 28:246-254.
37. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CTM, Roy Chowdhury J, Roy Chowdhury N, et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate glucuronosyltransferase. J Clin Invest 1994; 94:2385-2391.
38. Boase S, Miners JO. In-vitro-in-vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 2002; 54:493-503.
39. Ghosh SS, Sappal BS, Kalpana GV, Lee SW, Roy Chowdhury J, Roy Chowdhury N. Homodimerization of human bilirubin uridine diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications. J Biol Chem 2001; 276:42108-42115.
40. Boyd MA, Srasuebkul P, Ruxungtham K, Mackenzie PI, Uchaipichat V, Stek M, et al. Relationship between hyperbilirubinaemia and UDP- glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genom 2005; 16:321-329.
41. Fang J-L, Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8- dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 2004; 13:102-109.
42. Guilemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphism in uridine diphospho glucuronosyl transferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60:950-956.
43. Duguay Y, McGrath M, Lepine J, Gagne J-F, Hankinson SE, Colditz GA, et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 2004; 64:1202-1207.
44. Lin J-P, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006; 114:1476-1481.